Washington University School of Medicine
St Louis, Missouri, 63110, United States
NCT Number: NCT03151239
The purpose of the study is to understand the effect of the dietary supplement "Nicotinamide mononucleotide" on metabolic health in people.
Looking for future studies?
Notify Me55 year–75 year
Female
Interventional
Not applicable
St Louis, Missouri, 63110, United States
This study is is looking at the effect of the dietary supplement "Nicotinamide mononucleotide" (NMN) on key cardiovascular and metabolic functions, specifically those that are important risk factors for diabetes and cardiovascular disease. Accordingly, the investigators will evaluate the effect of NMN on how well the hormone insulin works to control blood sugar. The investigators will also look at the effects of NMN on blood lipids; body fat and liver fat; and other blood, fat tissue and muscle tissue markers of cardiovascular (heart) and metabolic health. Data from studies conducted in rodents have shown that NMN supplementation has beneficial effects on cardiovascular and metabolic health, but this has not yet been studied in people.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Intervention will last at least 8 weeks in the form of two capsules (250 mg total).
Other names: nicotinamide mononucleotide
Intervention will last at least 8 weeks in the form of two capsules.
Time frame: before and after at least 8 weeks of treatment
The outcome will be assessed by hyperinsulinemic-euglycemic clamp procedure in conjunction with stable isotopic tracer infusion before and after intervention period.
Time frame: before and after at least 8 weeks of treatment
The outcome will be assessed during hyperinsulinemic-euglycemic clamp procedure in conjunction with stable isotopic tracer infusion before and after intervention period.
Time frame: before and after at least 8 weeks of treatment
The outcome will be assessed during hyperinsulinemic-euglycemic clamp procedure in conjunction with stable isotopic tracer infusion before and after intervention period.
Time frame: before and after at least 8 weeks of treatment
The outcome will be measured by using dual-energy X-ray absorptiometry before and after intervention period.
Time frame: before and after at least 8 weeks of treatment
The outcome will be measured by using dual-energy X-ray absorptiometry before and after intervention period.
Time frame: before and after at least 8 weeks of treatment
The outcome will be measured by using magnetic resonance imaging before and after intervention period.
Time frame: before and after at least 8 weeks of treatment
The outcome will be measured by using magnetic resonance imaging before and after intervention period.
Time frame: before and after at least 8 weeks of treatment
The outcome will be assessed by measuring blood pressure at rest before and after intervention period.
Time frame: before and after at least 8 weeks of treatment
The outcome will be determined by plasma glucose concentration after overnight fasting, before and after intervention period.
Time frame: before and after at least 8 weeks of treatment
The outcome will be determined by plasma insulin concentration after overnight fasting, before and after intervention period.
Time frame: before and after at least 8 weeks of treatment
The outcome will be determined by plasma free fatty acid concentration after overnight fasting, before and after intervention period.
Time frame: before and after at least 8 weeks of treatment
The outcome will be assessed by measuring NAD content before and after intervention period
Time frame: before and after at least 8 weeks of treatment
The outcome will be determined by Western blot by using samples collected before and after intervention period
Washington University School of Medicine
Other
Effect of NMN (Nicotinomide Mononucleotide) Supplementation on Cardiometabolic Function
Acronym: NMN
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04571008
Glucose Metabolism Disorders, Metabolic Diseases
St Louis, Missouri, United States
View Trial DetailsNCT06619834
Diabetes Mellitus, Endocrine System Diseases
Ann Arbor, Michigan, United States
View Trial DetailsNCT05014204
Diabetes, Diabetes Mellitus
Los Angeles, California, United States
View Trial DetailsNCT05260021
Diabetes Mellitus, Diabetes Mellitus, Type 2
Los Angeles, California, United States
View Trial Details